Drug intelligence / Profile preview

NovaDerm

Development stage: Unknown
Lead developer: Regenicin
Modality: Cell Therapies
Administration: Topical

Overview

NovaDerm is Regenicin's proprietary regenerative cell therapy developed for skin restoration. It is composed of skin cells grown on specialized collagen scaffolds. Regenicin contracted Bovine Collagen Products (BCP) to manufacture these proprietary collagen scaffolds and Pure Med Farma (PMF) to supply the specific closed herd collagen required for the scaffolds. The therapy was in preparation for an Investigational New Drug (IND) submission to the FDA and subsequent Phase 1 clinical trials, with a global Clinical Research Organization (CRO) selected to manage its clinical development.

Brand names: NovaDerm

Beyond the preview

Go deeper on NovaDerm.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NovaDerm.

Explore the full profile